Palmiway is a 400 mg palmitic acid monoethanolamide (palmitoylethanolamide, PEA) capsule formulated to support healthy nerve function, reduce inflammatory pain, and improve overall comfort in chronic pain conditions. It is suitable as adjunct nutritional support for patients with neuropathic pain, nerve‑compression syndromes like sciatica or carpal tunnel, and chronic musculoskeletal discomfort under medical guidance.​

Palmitoylethanolamide (PEA) is an endocannabinoid‑like fatty acid amide produced naturally in the body that interacts primarily with PPAR‑α and other receptors involved in neuroinflammation and pain signalling. By down‑regulating pro‑inflammatory cytokines and mast‑cell activation, PEA dampens both peripheral and central sensitisation, leading to a clinically relevant reduction in chronic pain intensity over weeks of regular use.​

Typical regimens in clinical studies use 300–600 mg of PEA one to two times daily for 4–12 weeks, with dose and duration to be individualised by a physician or pain specialist. Palmiway should be used cautiously in pregnant or lactating women, children, or patients on multiple neuropathic or anticoagulant medicines, and users should seek medical advice if pain worsens, new neurological deficits appear, or any unusual reactions occur.